Berkeley Lovelace Jr.
CNBC, 15 May 2017
Exact Sciences Chairman and CEO Kevin Conroy fired back at a bearish assessment made by Citron Research’s Andrew Left, who predicted a long-term drop in the cancer testing company’s stock to a near-zero single digit.
Citron said in a report on Monday that Exact Sciences’ Cologuard cancer test, an at home screening for colon cancer, is “inferior” and shouldn’t be pitching it as an alternative to a colonoscopy.
Comment: Andrew Left’s Citron appears to be a front for naked short sellers.